Respiratorius (RESP) | Spotlight

Respiratorius is a research company. Today, the company is mainly focused on development of new drug candidates for the treatment of chronic obstructive pulmonary disease (COPD), asthma and cancer. Additionally, the company focuses on project development in the area of cardiovascular diseases. The company was formed in 1999 as a spin-off from Lund University. The company is based in Lund.

Quotes for Respiratorius AB

Right Now

+/-: 0.13
%: 14,13%
Latest: 1.05
High: 1.1
Low: 0.896
Volume: 535 805
Turnover (SEK): 546 372
Value (MSEK): 165,0

Board

CEO

Johan Drott

Chairman Of The Board

Christer Fåhræus

Board

Anna Törner
Ingemar Kihlström
Kristina Drott
Olov Sterner
Sarah Fredriksson

Articles of association

News

2020-03-30 16:33:35 Respiratorius - Finansiering säkerställd
2020-02-04 08:22:49 Bokslutskommuniké 1 jan - 31 dec 2019
2019-11-18 08:56:25 Respiratorius - Valberedning utsedd
2019-11-07 08:24:45 KVARTALSRAPPORT 3, 2019
2019-11-06 09:11:38 Canada grants patent for VAL001

Show More

News agencies

2020-03-30 16:41:47 Finwire: Respiratorius tar upp kortfristigt lån
2020-02-04 11:03:35 Finwire: Respiratorius behöver stärka kassan inom kort - Redeye
2020-02-04 08:32:08 Finwire: Respiratorius rapporterar något minskad förlust under fjärde kvartalet
2019-11-19 15:15:04 Finwire: Respiratorius fortsätter jakten på partner till VAL001
2019-11-18 10:00:47 Finwire: Respiratorius har utsett sin valberedning

Show More

Analysis

2019-03-19 SvD Börsplus: Emission eller exit?
2018-01-09 SvD Börsplus: Andlös spänning för Respiratorius inför årets ödesbesked
2014-11-18 Redeye: Väntans tider är goda tider
2014-07-21 Redeye: Lättare luft att andas

Videos

Upcoming reports

2020-05-19 Årsstämma 2019
2020-05-19 Delårsrapport 2020-Q1
2020-08-25 Delårsrapport 2020-Q2
2020-11-04 Delårsrapport 2020-Q3

Annual reports, prospectus etc.